Lung Cancer Clinical Trials

UC 16-01 –SUSPENDED--
Pathway Analyses for Individualized Network Therapeutics for Cancer (Ou)

UCI 14-25
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 15-79
Ph II Open-Label Randomized Radiosurgery w/ or w/o TT Fields for 1-10 Brain Metastases from NSCLC (Carrillo)

LUNG CANCER

- BLOOD DRAW ONLY
- DIAGNOSTIC
- FAILED PLATINUM-BASED CHEMO TX
- NEW DX OF BRAIN METS
- 1st LINE THERAPEUTIC

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**
**OPENING SOON**

UCI 07-40
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

UCI 16-96
A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Ou)

**UCI 17-50**
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumor (Ou)

**UCI 17-90**
A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**
Multiple Mutations

**UCI 17-83**
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (Ou)

**UCI 15-82**
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (Ou)

**ECOG-EAY131**
Molecular Analysis for Therapy Choice (MATCH) (Seery)

**UCI 16-79**
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**